"use strict";(self.webpackChunk_N_E=self.webpackChunk_N_E||[]).push([[977],{48539:(e,t,a)=>{a.d(t,{T:()=>h});var i=a(95155),r=a(28820),n=a(38397),o=a(12115),s=a(16189),l=a(2621),c=a(19086),d=a(64869),u=a(71897);let m=/^(https?|ircs?|mailto|xmpp)$/i;function p(e){let t=e.indexOf(":"),a=e.indexOf("?"),i=e.indexOf("#"),r=e.indexOf("/");return -1===t||-1!==r&&t>r||-1!==a&&t>a||-1!==i&&t>i||m.test(e.slice(0,t))?e:""}function h(e){let{as:t,children:a,className:m,components:h,remarkPlugins:y=[],rehypePlugins:b=[],allowedElements:C,disallowedElements:v,unwrapDisallowed:R=!1,skipHtml:g=!1,urlTransform:S=p}=e,f=o.useMemo(()=>{if(!a)return null;let e=(0,d.l)().use(l.A).use(y).use(c.A,{allowDangerousHtml:!0}).use(s.A).use(b),t=e.runSync(e.parse(a));if((C||v||g||S)&&(0,u.YR)(t,(e,t,a)=>{if("raw"===e.type&&a&&"number"==typeof t)return g?a.children.splice(t,1):a.children[t]={type:"text",value:e.value},t;if("element"===e.type){for(let t in n.$)if(Object.hasOwn(n.$,t)&&Object.hasOwn(e.properties,t)){let a=e.properties[t],i=n.$[t];(null===i||i.includes(e.tagName))&&(e.properties[t]=S(String(a||""),t,e))}}if("element"===e.type&&a&&"number"==typeof t&&(C?!C.includes(e.tagName):!!v&&v.includes(e.tagName)))return R&&e.children?a.children.splice(t,1,...e.children):a.children.splice(t,1),t}),!a.includes("\n")&&t.children&&1===t.children.length){let e=t.children[0];"element"===e.type&&"p"===e.tagName&&(t.children=e.children)}return(0,r.H)(t,{jsx:i.jsx,jsxs:i.jsxs,components:h||{},passNode:!0,Fragment:o.Fragment,development:!1})},[a,h,y,b,C,v,R,g,S]);return(0,i.jsx)(t||"div",{className:m,children:f})}},58098:e=>{e.exports=JSON.parse('{"NCT07252232":{"acronym":"RASolute 304","nctId":"NCT07252232","interventions":"Daraxonrasib (RMC-6236)","cardTitle":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":3,"phase":"3 (open-label)","phase2":"3 (open-label)","phaseFull":"Phase 3","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)","conditions":"Pancreatic ductal adenocarcinoma (PDAC)","clinicalTrialPageDescription":"This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib (RMC-6236) will improve disease-free survival (DFS) compared to standard of care (SOC) observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.","clinicalTrialPageDescriptionMinimal":"Resected PDAC","selectedEligibilityCriteria":"* Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease\\r\\n* Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy\\r\\n* Must have completed most recent treatment within the past 12 weeks\\r\\n* Documented RAS mutation status","eligibilityFootnote":"","startDate":"2025-12-01","completionDate":"2030-07-01","detailedDescription":"This is a global, randomized, open-label, **Phase 3** study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to standard of care (SOC) observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.","countries":"Puerto Rico, United States","allocation":"RANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":500,"interventionModel":"PARALLEL ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years old and has provided informed consent\\r\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\r\\n* Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease\\r\\n* Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy\\r\\n* Must have completed most recent treatment within the past 12 weeks\\r\\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\\r\\n* Documented RAS mutation status\\r\\n* Able to take oral medications\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Prior therapy with direct RAS‑targeted therapy (e.g., degraders and/or inhibitors)\\r\\n* Any conditions that may affect the ability to take or absorb study drug\\r\\n* Major surgery within 28 days prior to randomization\\r\\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures","eligibilityCriteriaFootnote":"","primaryOutcomes":"Disease-free survival (DFS) per investigator assessment","secondaryOutcomes":"Overall survival (OS), DFS per blinded independent central review (BICR), DFS rate at 1 year and 2 years, OS rate at 1 year and 2 years, safety and tolerability of daraxonrasib, pharmacokinetics of daraxonrasib","references":"Study of daraxonrasib (RMC-6236) in patients with resected pancreatic ductal adenocarcinoma (PDAC) (RASolute 304). ClinicalTrials.gov identifier: NCT07252232. Updated November 26, 2025. Accessed November 26, 2025. <a href=\\"https://www.clinicaltrials.gov/study/NCT07252232\\" target=\\"_blank\\">https://www.clinicaltrials.gov/study/NCT07252232</a>","cancerTypeTable":"Pancreatic ductal adenocarcinoma (PDAC)","cancerTypeAbbr":"PDAC","descriptionTable":"RASolute 304 is a Phase 3 study designed to evaluate whether daraxonrasib (RMC-6236) will improve disease-free survival (DFS) compared to standard of care (SOC) observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy","selectedEligibilityCriteriaTable":"* Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease\\r\\n* Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy\\r\\n* Must have completed most recent treatment within the past 12 weeks\\r\\n* Documented RAS mutation status","statusTable":"actively recruiting"},"NCT06881784":{"acronym":"RASolve 301","nctId":"NCT06881784","interventions":"Daraxonrasib (RMC-6236)","cardTitle":"Phase 3 Multicenter, Open Label, Randomized Study of Daraxonrasib (RMC‑6236) Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] Non-Small Cell Lung Cancer (NSCLC)","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":3,"phase":"3 (open-label)","phase2":"3 (open-label)","phaseFull":"Phase 3","conditionsForStudy":"* Non-small cell lung cancer (NSCLC)","conditions":"Non-small cell lung cancer (NSCLC)","clinicalTrialPageDescription":"This global, randomized, Phase 3 trial is designed to evaluate daraxonrasib (RMC‑6236) compared to docetaxel chemotherapy in patients with previously treated, locally advanced or metastatic RAS‑mutant NSCLC.","clinicalTrialPageDescriptionMinimal":"Previously treated, locally advanced or metastatic RAS mutant NSCLC","selectedEligibilityCriteria":"* Confirmed locally advanced or metastatic disease\\r\\n* Documented RAS mutation status\\r\\n* No prior therapy with direct RAS‑targeted therapy or docetaxel\\r\\n* No untreated central nervous system (CNS) metastases","eligibilityFootnote":"","startDate":"2025-05-10","completionDate":"2030-12-01","detailedDescription":"This is a global, randomized, open-label, **Phase 3** study designed to evaluate whether treatment with daraxonrasib (RMC‑6236) will improve progression-free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib (RMC‑6236) or docetaxel chemotherapy.","countries":"Belgium, France, Germany, Hong Kong, Ireland, Italy, Japan, Netherlands, Poland, Puerto Rico, Singapore, Switzerland, Taiwan, United States","allocation":"RANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":420,"interventionModel":"PARALLEL\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years old and has provided informed consent\\r\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\r\\n* Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy\\r\\n* Measurable disease per RECIST v1.1\\r\\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\\r\\n* One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy\\r\\n* Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)\\r\\n* Able to take oral medications\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Prior therapy with direct RAS‑targeted therapy or docetaxel\\r\\n* Untreated central nervous system (CNS) metastases\\r\\n* Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function)\\r\\n* Ongoing anticancer therapy\\r\\n* Pregnant or breastfeeding","eligibilityCriteriaFootnote":"","primaryOutcomes":"Progression-free survival (PFS) per Investigator and overall survival (OS) in the RAS G12X-C population (i.e., RAS G12X excluding G12C)","secondaryOutcomes":"PFS in the RAS (MUT) population per Investigator, OS in the RAS (MUT) population objective response per investigator in the RAS (G12X-C) and RAS (MUT) populations, PFS per BICR in the RAS (G12X-C) and RAS (MUT) populations, objective response per BICR in the RAS (G12X-C) and RAS (MUT) populations, duration of response (DOR) per investigator and BICR in the RAS (G12X-C) and RAS (MUT) populations, time to response (TTR) per Investigator and per BICR in the RAS (G12X-C) and RAS (MUT) populations, treatment effect on quality of life (QoL) using EORTC QLQ-LC13 In the RAS (G12X-C) and RAS (MUT) populations, treatment effect on quality of life (QoL) using EORTC QLQ-C30 In the RAS (G12X-C) and RAS (MUT) populations, safety and tolerability in the RAS (G12X-C) and RAS (MUT) populations, and PK characterization of daraxonrasib in the RAS (MUT) population","references":"Study of daraxonrasib (RMC‑6236) in patients with RAS mutated NSCLC (RASolve 301). ClinicalTrials.gov identifier: NCT06881784. Updated November 12, 2025. Accessed November 26, 2025. <a href=\\"https://www.clinicaltrials.gov/study/NCT06881784\\" target=\\"_blank\\">https://www.clinicaltrials.gov/study/NCT06881784</a>","cancerTypeTable":"Non-small cell lung cancer (NSCLC)","cancerTypeAbbr":"NSCLC","descriptionTable":"RASolve 301 is a Phase 3 trial designed to evaluate daraxonrasib (RMC‑6236) compared to docetaxel chemotherapy in patients with previously treated, locally advanced or metastatic RAS‑mutated NSCLC","selectedEligibilityCriteriaTable":"* Confirmed locally advanced or metastatic disease\\r\\n* Documented RAS mutation status\\r\\n* No prior therapy with direct RAS‑targeted therapy or docetaxel\\r\\n* No untreated central nervous system metastatic disease","statusTable":"Actively Recruiting"},"NCT06625320":{"acronym":"RASolute 302","nctId":"NCT06625320","interventions":"Daraxonrasib (RMC-6236)","cardTitle":"Phase 3 Study of Daraxonrasib (RMC‑6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)","overallStatus":"NOT RECRUITING","status":"Active, NOT RECRUITING","phaseNumber":3,"phase":"3 (open-label)","phase2":"3 (open-label)","phaseFull":"Phase 3","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Pancreatic cancer","conditions":"Pancreatic ductal adenocarcinoma (PDAC), pancreatic cancer","clinicalTrialPageDescription":"This global, randomized, Phase 3 trial is designed to evaluate daraxonrasib (RMC‑6236) compared to standard(s) of care (SOC) treatment in patients with previously treated metastatic PDAC.","clinicalTrialPageDescriptionMinimal":"Previously treated metastatic PDAC","selectedEligibilityCriteria":"* Confirmed metastatic disease\\r\\n* Documented RAS mutation status, either mutant or wild-type\\r\\n* No prior therapy with direct RAS‑targeted therapy\\r\\n* No history of known central nervous system (CNS) metastatic disease","eligibilityFootnote":"","startDate":"2024-10-16","completionDate":"2027-12-01","detailedDescription":"This is a global, randomized, open-label, **Phase 3** study designed to evaluate whether treatment with daraxonrasib (RMC‑6236) will improve progression free survival (PFS) or overall survival (OS) compared to Investigator\'s choice of standard of care chemotherapy in patients with metastatic PDAC who were previously treated with one prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen. Patients will be randomized in a 1:1 ratio to receive daraxonrasib (RMC‑6236) (Arm A) or Investigator\'s choice of standard of care chemotherapy (Arm B).","countries":"France, Germany, Italy, Japan, Puerto Rico, Spain, United States","allocation":"RANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":460,"interventionModel":"PARALLEL ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years old and has provided informed consent\\r\\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\\r\\n* Histologically or cytologically confirmed PDAC with metastatic disease\\r\\n* Measurable disease per RECIST 1.1\\r\\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\\r\\n* Documented RAS mutation status, either mutant or wild-type. RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)\\r\\n* Able to take oral medications\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Prior therapy with direct RAS‑targeted therapy (e.g., degraders and/or inhibitors)\\r\\n* History of or known central nervous system metastatic disease\\r\\n* Any conditions that may affect the ability to take or absorb study treatment\\r\\n* Major surgery within 4 weeks prior to randomization\\r\\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures","eligibilityCriteriaFootnote":"","primaryOutcomes":"Progression-free survival (PFS) and overall survival (OS) in the RAS G12-mutant population","secondaryOutcomes":"PFS and OS in the all-patient population, objective response in the RAS G12-mutant and all-patient populations, time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26) in the RAS G12-mutant and all-patient populations, time to deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in the RAS G12-mutant and all-patient populations, objective response per investigator in RAS G12-mutant and all-patient populations, duration of response (DOR) in RAS G12-mutant and all-patient populations, time to response (TTR) in RAS G12-mutant and all-patient populations, percentage of patients with adverse events (AEs), pharmacokinetics of RMC-6236 in RAS G12-mutant and all-patient populations","references":"Phase 3 study of daraxonrasib (RMC‑6236) in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) (RASolute 302). ClinicalTrials.gov identifier: NCT06625320. Updated December 12, 2025. Accessed December 12, 2025. <a href=\\"https://www.clinicaltrials.gov/study/NCT06625320\\" target=\\"_blank\\">https://www.clinicaltrials.gov/study/NCT06625320</a>","cancerTypeTable":"Pancreatic ductal adenocarcinoma (PDAC)","cancerTypeAbbr":"PDAC","descriptionTable":"RASolute 302 is a Phase 3 study that compares the RAS(ON) inhibitor daraxonrasib (RMC‑6236) with standard of care chemotherapy in patients with PDAC that has spread to other parts of the body (metastatic) and has been previously treated","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* Documented RAS\xa0mutation status, either mutant or wild type\\r\\n    * RAS mutations defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)\\r\\n* Previously treated with 1 prior line of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen \\r\\n* No history of known central nervous system metastatic disease\\r\\n* No previous\xa0RAS‑directed therapies\\r\\n* No major surgery within 4 weeks of starting the trial","statusTable":"active, not recruiting"},"NCT06162221":{"acronym":"RMC-LUNG-101","nctId":"NCT06162221","interventions":"Daraxonrasib (RMC-6236), Zoldonrasib (RMC-9805), Elironrasib (RMC-6291)","cardTitle":"Study of RAS(ON) Inhibitor Combination or Monotherapy in Patients With Advanced RAS-mutated NSCLC","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":2,"phase":"1b/2 (open-label)","phase2":"","phaseFull":"Phase 1b/Phase 2","conditionsForStudy":"* Non-small cell lung cancer (NSCLC)\\r\\n* KRAS, NRAS, HRAS mutant NSCLC\\r\\n* KRAS G12C mutant solid tumors, lung cancer\\r\\n* Lung cancer Stage IV, advanced solid tumor\\r\\n* RAS G12D mutant NSCLC","conditions":"Non-small cell lung cancer (NSCLC); KRAS, NRAS, HRAS mutant NSCLC; KRAS G12C mutant solid tumors, lung cancer; lung cancer stage IV, advanced solid tumor, cancer; RAS G12D mutant NSCLC","clinicalTrialPageDescription":"This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of 3 novel RAS(ON) inhibitors, elironrasib (RMC-6291), zoldonrasib (RMC-9805) and/or daraxonrasib (RMC-6236), with SOC, or zoldonrasib as monotherapy, in patients with advanced or metastatic NSCLC or other advanced solid tumors.","clinicalTrialPageDescriptionMinimal":"Locally advanced or metastatic NSCLC or other advanced solid tumors","selectedEligibilityCriteria":"* Advanced or metastatic KRAS G12C mutant solid tumor not amenable to curative surgery<sup>b</sup>\\r\\n* Advanced or metastatic RAS mutant NSCLC<sup>b</sup>\\r\\n* Advanced or metastatic RAS G12D mutant NSCLC<sup>b</sup>\\r\\n* Adequate organ function\\r\\n* Received appropriate prior standard therapy\\r\\n* No primary central nervous system (CNS) tumors","eligibilityFootnote":"","startDate":"2024-01-18","completionDate":"2028-12","detailedDescription":"This is an open-label platform **Phase 1b/2** study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), or zoldonrasib as monotherapy and to define the Recommended **Phase 2** Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.\\r\\n\\r\\nSubprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291, with or without RMC-6236, in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutant advanced solid tumors.\\r\\n\\r\\nSubprotocol B is an open-label, multicenter, Phase 1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS‑mutant non-small cell lung cancer (NSCLC).\\r\\n\\r\\nSubprotocol C is an open-label, multicenter, Phase 1b/2 study of RMC-9805 with or without RMC-6236, in combination with other anticancer agents, in patients with RAS G12D-mutant non-small cell lung cancer (NSCLC).\\r\\n\\r\\nSubprotocol D is an open-label, multicenter, Phase 2 study of RMC-9805 in previously treated patients with RAS G12D-mutant non-small cell lung cancer (NSCLC).\\r\\n\\r\\nSubprotocols A, B, and C consist of two parts: Part 1—Dose Exploration and Part 2—Dose Expansion. Subprotocol D consists of only one part.","countries":"Australia, France, Germany, Greece, Italy, Netherlands, Spain, Taiwan, United States","allocation":"NONRANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":616,"interventionModel":"PARALLEL\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE\xa0(open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\nAll Patients (unless otherwise noted):\\r\\n* ≥18 years of age\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Adequate organ function as outlined by the study\\r\\n* Received prior standard therapy appropriate for tumor type and stage\\r\\n* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutant solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)\\r\\n* Must have pathologically documented, locally advanced or metastatic RAS‑mutant NSCLC (Subprotocol B)\\r\\n* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutant NSCLC (Subprotocol C and Subprotocol D)\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\nAll Patients:\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\\r\\n* Major surgery within 28 days of first dose\\r\\n* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids","eligibilityCriteriaFootnote":"<sup>b</sup>These criteria are for specific subprotocols within the clinical trial. Refer to the ClinicalTrials.gov record for more information.","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Maximum observed blood concentration (C<sub>max</sub>), time to reach maximum blood concentration (T<sub>max</sub>), area under blood concentration time curve (AUC), objective response rate (ORR), duration of response (DOR), drug concentrations over time","references":"Study of RAS(ON) inhibitor combinations in patients with advanced RAS‑mutated NSCLC. ClinicalTrials.gov identifier: NCT06162221. Updated November 6, 2025. Accessed November 26, 2025. <a href=\\"https://clinicaltrials.gov/study/NCT06162221\\" target=\\"_blank\\">https://clinicaltrials.gov/study/NCT06162221</a>","cancerTypeTable":"Non-small cell lung cancer (NSCLC)","cancerTypeAbbr":"NSCLC","descriptionTable":"RMC-LUNG-101 is a Phase 1b/2 study investigating 3 RAS(ON) inhibitors, elironrasib (RMC-6291), zoldonrasib (RMC-9805) and/or daraxonrasib (RMC-6236), with SOC, or zoldonrasib as monotherapy, in patients with advanced or metastatic NSCLC or other advanced solid tumors","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* KRAS G12C, RAS G12D, or other RAS mutations\\r\\n* Received prior standard therapy appropriate for tumor type and stage\\r\\n* No major surgery <br/> \\\\<28 days of first dose\\r\\n* No primary central nervous system tumors\\r\\n* No active or history of interstitial lung disease or pneumonitis requiring steroids","statusTable":"actively recruiting"},"NCT07349537":{"acronym":"RMC-5127-001","nctId":"NCT07349537","interventions":"Daraxonrasib (RMC-6236), RMC-5127","cardTitle":"Study of RMC-5127 as Monotherapy and in Combination With Daraxonrasib (RMC-6236) or Cetuximab in Participants With Advanced KRAS G12V Mutant Solid Tumors","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":1,"phase":"1/1b (open-label)","phase2":"","phaseFull":"Phase 1/Phase 1b","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Non-small cell lung cancer (NSCLC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Advanced solid tumors","conditions":"Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors","clinicalTrialPageDescription":"This study is designed to evaluate the safety, tolerability, PK, and efficacy of RMC-5127, as monotherapy and in combination with daraxonrasib (RMC-6236) or cetuximab, in patients with advanced KRAS G12V mutant solid tumors.      ","clinicalTrialPageDescriptionMinimal":"Locally advanced or metastatic KRAS G12V mutant solid tumors","selectedEligibilityCriteria":"* Locally advanced or metastatic disease that is KRAS G12V mutant\\r\\n* Received and progressed or been intolerant to prior standard therapy (including including non–RAS-targeted therapy) appropriate for tumor type and stage\\r\\n* No primary central nervous system (CNS) tumors\\r\\n* No previous direct RAS-targeted therapy (including KRAS G12V inhibitors)","eligibilityFootnote":"","startDate":"2026-01-01","completionDate":"2028-10-01","detailedDescription":"This open-label, multicenter, **Phase 1/1b** study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity of RMC-5127, a selective and orally bioavailable KRAS G12V(ON) inhibitor, in patients with advanced KRAS G12V mutant solid tumors. The study consists of 3 arms: an RMC-5127 monotherapy arm, an RMC-5127 plus daraxonrasib combination arm, and an RMC-5127 plus cetuximab combination arm. All arms consist of 2 parts: Part 1—dose exploration and Part 2—dose expansion. Both parts of the monotherapy arm may include food effect cohorts.","countries":"United States","allocation":"NONRANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":574,"interventionModel":"PARALLEL\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years old \\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Pathologically documented, locally advanced or metastatic KRAS G12V mutated solid tumor malignancy\\r\\n* Received and progressed or been intolerant to prior standard therapy (including non–RAS-targeted therapy) appropriate for tumor type and stage\\r\\n* Adequate organ function (bone marrow, liver, kidney, coagulation)\\r\\n* Able to take oral medications\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (e.g., degraders and/or inhibitors)\\r\\n* Any conditions that may affect the ability to take or absorb study drug\\r\\n* Major surgery within 28 days prior to receiving study drug(s) ","eligibilityCriteriaFootnote":"","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs), changes in vital signs, clinical laboratory test values, and ECG test values","secondaryOutcomes":"Objective response rate (ORR), duration of response (DOR), pharmacokinetics (PK)","references":"Study of RMC-5127 in patients with advanced KRAS G12V mutant solid tumors. ClinicalTrials.gov identifier: NCT07349537. Updated January 26, 2026. Accessed January 26, 2026. <a href=\\"https://www.clinicaltrials.gov/study/NCT07349537\\" target=\\"_blank\\">https://www.clinicaltrials.gov/study/NCT07349537</a> ","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"","descriptionTable":"RMC-5127-001 is a Phase 1/1b study investigating PK and preliminary clinical activity of RMC-5127, either as monotherapy or in combination with daraxonrasib (RMC-6236) or cetuximab, in patients with advanced or metastatic KRAS G12V mutant solid tumors, such as NSCLC, PDAC, and CRC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* Documented KRAS G12V mutation\\r\\n* Received and progressed or been intolerant to prior standard therapy appropriate for tumor type and stage \\r\\n* No previous direct RAS‑targeted therapies (including G12V inhibitors)\\r\\n* No primary central nervous system tumors\\r\\n* Any conditions that may affect the ability to take or absorb study drug\\r\\n* Major surgery within 28 days prior to receiving study drug(s)","statusTable":"actively recruiting"},"NCT06040541":{"acronym":"RMC-9805-001","nctId":"NCT06040541","interventions":"Daraxonrasib (RMC-6236), Zoldonrasib (RMC-9805)","cardTitle":"Study of Zoldonrasib (RMC-9805) in Participants With KRAS G12D Mutant Solid Tumors","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":1,"phase":"1/1b (open-label)","phase2":"","phaseFull":"Phase 1/Phase 1b","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Non-small cell lung cancer (NSCLC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Advanced solid tumors","conditions":"Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors","clinicalTrialPageDescription":"This study is designed to evaluate the safety and tolerability of zoldonrasib (RMC‑9805) as monotherapy and in combination with daraxonrasib (RMC‑6236) in adults with KRAS G12D-mutant solid tumors.","clinicalTrialPageDescriptionMinimal":"Previously treated, locally advanced or metastatic KRAS G12D mutant solid tumors","selectedEligibilityCriteria":"* Locally advanced or metastatic disease that is KRAS G12D mutant\\r\\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy)\\r\\n* No primary central nervous system (CNS) tumors","eligibilityFootnote":"","startDate":"2023-09-07","completionDate":"2027-04-30","detailedDescription":"This is an open-label, multicenter, **Phase 1/1b** study of RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor, in subjects with KRAS G12D-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of 2 arms: RMC-9805 monotherapy arm and RMC-9805 plus RMC-6236 combination arm. Both arms consist of 2 parts: Part 1—dose exploration and Part 2—dose expansion.","countries":"United States","allocation":"NONRANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":604,"interventionModel":"PARALLEL\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation\\r\\n* Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Adequate organ function\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Known or suspected leptomeningeal or active brain metastases or spinal cord compression\\r\\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\\r\\n* Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS‑targeted therapy (eg, degraders and inhibitors)","eligibilityCriteriaFootnote":"","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Maximum observed blood concentration (C<sub>max</sub>), time to reach maximum blood concentration (T<sub>max</sub>), area under blood concentration time curve (AUC), accumulation ratio, elimination half-life (t1/2), overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS)","references":"Study of RMC-9805 in participants with KRAS G12D-mutant solid tumors. ClinicalTrials.gov identifier: NCT06040541. Updated August 28, 2025. Accessed October 22, 2025. <a href=\\"https://clinicaltrials.gov/study/NCT06040541\\" target=\\"_blank\\">https://clinicaltrials.gov/study/NCT06040541</a>","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"Advanced solid tumors","descriptionTable":"RMC-9805-001 is a Phase 1/1b study that investigates zoldonrasib (RMC-9805) alone or in combination with daraxonrasib (RMC‑6236) in patients with advanced or metastatic solid tumors, such as NSCLC, PDAC, and CRC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* KRAS G12D mutation\\r\\n* Received prior therapy\\r\\n* No previous RAS‑directed therapies\\r\\n* No primary central nervous system tumors or active brain metastasis","statusTable":"actively recruiting"},"NCT06445062":{"acronym":"RMC-GI-102","nctId":"NCT06445062","interventions":"Daraxonrasib (RMC-6236), Zoldonrasib (RMC-9805)","cardTitle":"Study of RAS(ON) inhibitors in Patients With Gastrointestinal Solid Tumors","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":2,"phase":"1/2 (open-label)","phase2":"","phaseFull":"Phase 1/Phase 2","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Gastrointestinal cancer","conditions":"Pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), gastrointestinal cancer","clinicalTrialPageDescription":"This platform study is designed to evaluate combinations of RAS(ON) inhibitors with other anticancer agents in patients with RAS‑mutant solid tumors with a focus on gastrointestinal cancers.","clinicalTrialPageDescriptionMinimal":"Previously treated and treatment-na\xefve solid tumors, particularly gastrointestinal tumors","selectedEligibilityCriteria":"* Documented pancreatic carcinoma\\r\\n* Poorly differentiated pancreatic carcinoma with metastatic disease\\r\\n* RAS mutant confirmed colorectal adenocarcinoma with unresectable or metastatic disease<sup>b</sup>\\r\\n* Presence of RAS G12D mutation<sup>b</sup>\\r\\n* No primary central nervous system (CNS) tumors or impaired gastrointestinal function","eligibilityFootnote":"<sup>b</sup>These criteria are for specific subprotocols within the clinical trial. Refer to the ClinicalTrials.gov record for more information.","startDate":"2024-05-24","completionDate":"2027-07-15","detailedDescription":"This is an open-label platform study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with standard of care (SOC) or with novel agents, and to define the recommended **Phase 2** dose and schedule (RP2DS). Enrollment of patients with RAS mutations will be specified in each subprotocol.\\r\\n\\r\\nSubprotocol A is an open-label, multicenter study of RMC-6236 in combination with 5-fluorouracil-based regimens in patients with treatment-na\xefve unresectable or metastatic colorectal cancer or treatment-na\xefve metastatic pancreatic ductal adenocarcinoma. Subprotocol B is an open-label, multicenter study of RMC-6236 in combination with cetuximab with or without mFOLFOX6 in patients with unresectable or metastatic colorectal cancer or patients with previously treated or treatment-na\xefve metastatic pancreatic ductal adenocarcinoma. Subprotocol C is an open-label, multicenter study of RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with treatment-na\xefve metastatic pancreatic ductal adenocarcinoma. Subprotocol D is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with 5-fluorouracil-based regimens in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol E is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with cetuximab-based therapies with or without mFOLFOX6 in patients with RAS G12D-mutant unresectable or metastatic colorectal cancer or metastatic pancreatic ductal adenocarcinoma. Subprotocol F is an open-label, multicenter study of RMC-9805 with or without RMC-6236 in combination with gemcitabine and nab-paclitaxel in patients with RAS G12D-mutant metastatic pancreatic ductal adenocarcinoma.\\r\\n\\r\\nEach subprotocol consists of 2 parts: Part 1—Dose Exploration and Part 2—Dose Expansion.","countries":"United States","allocation":"NONRANDOMIZED","primaryPurpose":"TREATMENT","enrollmentInfo":1130,"interventionModel":"PARALLEL ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\nAll Patients (unless otherwise noted):\\r\\n* ≥18 years of age\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Adequate organ function as outlined by the study\\r\\n* Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS‑mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, and C)\\r\\n* Presence of RAS G12D mutation (Subprotocol D, E, F)\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\nAll Patients:\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\\r\\n* Major surgery within 28 days of first dose","eligibilityCriteriaFootnote":"<sup>b</sup>These criteria are for specific subprotocols within the clinical trial. Refer to the ClinicalTrials.gov record for more information.","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Pharmacokinetics, overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS)","references":"Study of RAS(ON) inhibitors in patients with gastrointestinal solid tumors. ClinicalTrials.gov identifier: NCT06445062. Updated October 28, 2025. Accessed November 26, 2025. <a href=\\"https://www.clinicaltrials.gov/study/NCT06445062\\" target=\\"_blank\\">https://www.clinicaltrials.gov/study/NCT06445062</a>","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"Advanced solid tumors","descriptionTable":"RMC-GI-102 is a Phase 1/2 study that investigates 2 RAS(ON) inhibitors (daraxonrasib [RMC-6236] and zoldonrasib [RMC-9805]) combined with the standard of care or other new therapeutics in patients with metastatic solid tumors, such as CRC and PDAC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* RAS mutations, including G12D\\r\\n* No primary central nervous system tumors or impaired gastrointestinal function\\r\\n* No major surgery within 28 days of first dose","statusTable":"actively recruiting"},"NCT06128551":{"acronym":"RMC-6291-101","nctId":"NCT06128551","interventions":"Daraxonrasib (RMC-6236), Elironrasib (RMC-6291)","cardTitle":"Study of Elironrasib (RMC-6291) in Combination With Daraxonrasib (RMC-6236) in Participants With Advanced KRAS G12C Mutant Solid Tumors","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":1,"phase":"1b (open-label)","phase2":"","phaseFull":"Phase 1b","conditionsForStudy":"* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Non-small cell lung cancer (NSCLC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Advanced solid tumors","conditions":"Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC)","clinicalTrialPageDescription":"This study is designed to evaluate the safety, tolerability, and pharmacokinetic profiles of elironrasib (RMC-6291) and daraxonrasib (RMC‑6236) in adults with KRAS G12C‑mutant solid tumors.","clinicalTrialPageDescriptionMinimal":"Previously treated advanced or metastatic KRAS G12C mutant solid tumors","selectedEligibilityCriteria":"* Advanced or metastatic disease that is KRAS G12C mutant and not amenable to curative therapy\\r\\n* Adequate organ function\\r\\n* No primary central nervous system (CNS) tumors\\r\\n* No active brain metastases","eligibilityFootnote":"","startDate":"2023-11-14","completionDate":"2026-11-30","detailedDescription":"This is an open-label, multicenter, **Phase 1b** study of elironrasib in combination with daraxonrasib in participants with advanced KRAS G12C-mutant solid tumors, to identify the maximum tolerated dose (MTD) and/or recommended **Phase 2** dose and schedule (RP2DS) and provide a preliminary assessment of the antitumor activity of elironrasib in participants with KRAS G12C tumors. \\r\\n\\r\\nThe study consists of 2 parts: Part 1—Dose Escalation and Part 2—Dose Expansion.","countries":"France, Germany, Italy, Netherlands, Puerto Rico, Spain, United States","allocation":"Not Applicable","primaryPurpose":"TREATMENT","enrollmentInfo":210,"interventionModel":"SINGLE GROUP ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE (open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years of age\\r\\n* Histology: pathologically documented, KRAS G12C-mutant, advanced or metastatic solid tumors not amendable to curative therapy\\r\\n* Part 1. Dose Escalation: solid tumors, previously treated&#x20;\\r\\n* Part 2. Dose Expansion:\\r\\n    * NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C(OFF) inhibitors\\r\\n    * NSCLC, previously treated with immunotherapy and chemotherapy, na\xefve to KRAS G12C(OFF) inhibitors\\r\\n    * NSCLC, previously treated with immunotherapy, chemotherapy, with untreated, asymptomatic central nervous system (CNS) metastases \\\\<2 cm in size\\r\\n    * Solid tumors, previously treated, na\xefve to KRAS G12C(OFF) inhibitors\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Adequate organ function\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Active brain metastases\\r\\n* Known impairment of GI function that would alter the absorption\\r\\n* Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment","eligibilityCriteriaFootnote":"","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Maximum observed blood concentration (C<sub>max</sub>), time to reach maximum blood concentration (T<sub>max</sub>), area under blood concentration time curve (AUC), accumulation ratio, elimination half-life (t1/2), overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS)","references":"Study of RMC-6291 in combination with RMC-6236 in participants with advanced KRAS G12C mutant solid tumors. ClinicalTrials.gov identifier: NCT06128551. Updated March 27, 2025. Accessed April 7, 2025. <a href=\\"https://clinicaltrials.gov/study/NCT06128551\\" target=\\"_blank\\">https://clinicaltrials.gov/study/NCT06128551</a>","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"Advanced solid tumors","descriptionTable":"RMC-6291-101 is a Phase 1b study investigating the combination of RAS(ON) inhibitors elironrasib (RMC-6291) and daraxonrasib (RMC‑6236) in patients with advanced or metastatic solid tumors, such as NSCLC, CRC, and PDAC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* KRAS G12C mutation\\r\\n* Received previous treatment\\r\\n* No primary central nervous system tumors or active brain metastasis\\r\\n* No major surgery within 28 days of first dose\\r\\n* No minor procedures within 7 days of treatment","statusTable":"actively recruiting"},"NCT05462717":{"acronym":"RMC-6291-001","nctId":"NCT05462717","interventions":"Elironrasib (RMC-6291)","cardTitle":"Dose Escalation and Dose Expansion Study of Elironrasib (RMC-6291) Monotherapy in Subjects With Advanced KRAS G12C Mutant Solid Tumors","overallStatus":"NOT RECRUITING","status":"Active, NOT RECRUITING","phaseNumber":1,"phase":"1/1b (open-label)","phase2":"","phaseFull":"Phase 1/Phase 1b","conditionsForStudy":"* Non-small cell lung cancer (NSCLC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Advanced solid tumors","conditions":"Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors","clinicalTrialPageDescription":"This open-label, multicenter, phase 1/1b trial is designed to evaluate elironrasib (RMC‑6291) monotherapy in patients with advanced KRAS G12C-mutant solid tumors. The study will include 2 components: a Dose-Escalation and a Dose-Expansion.","clinicalTrialPageDescriptionMinimal":"Locally advanced or metastatic KRAS G12C mutant solid tumors","selectedEligibilityCriteria":"* Confirmed locally advanced or metastatic solid tumor malignancy\\r\\n* Documented KRAS G12C mutation\\r\\n* No prior therapy with a KRAS G12C(ON) inhibitor\\r\\n* No primary central nervous system (CNS) tumors","eligibilityFootnote":"","startDate":"2022-09-14","completionDate":"2025-12-30","detailedDescription":"This open-label, multicenter, **Phase 1/1b** trial is designed to evaluate elironrasib (RMC-6291) monotherapy in patients with advanced KRAS G12C-mutant solid tumors. The study will include 2 components: a Dose—Escalation and a Dose—Expansion.","countries":"Australia, Czechia, France, Italy, Malaysia, Poland, Republic of Korea, Serbia, Singapore, Spain, Taiwan, Thailand, United States","allocation":"Not Applicable","primaryPurpose":"TREATMENT","enrollmentInfo":222,"interventionModel":"SINGLE GROUP\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE\xa0(open-label)","eligibilityCriteria":"**Inclusion Criteria**\\r\\n\\r\\n* ≥18 years of age\\r\\n* Pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for, standard-of-care anticancer treatments\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\xa0\\r\\n* Prior treatment with a KRAS G12C(OFF) inhibitor allowed for dose escalation\\r\\n* Adequate organ function\\r\\n\\r\\n**Exclusion Criteria**\\r\\n\\r\\n* Primary central nervous system (CNS) tumor\\r\\n* Active brain metastases\\r\\n* Known impairment of GI function that would alter the absorption\\r\\n* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment\\r\\n* Prior therapy with KRAS G12C(ON) inhibitor","eligibilityCriteriaFootnote":"","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Maximum observed blood concentration (C<sub>max</sub>), time to reach maximum blood concentration (T<sub>max</sub>), area under blood concentration time curve (AUC), accumulation ratio, elimination half-life (t1/2), overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS)","references":"Dose escalation and dose expansion study of RMC-6291 monotherapy in subjects with advanced KRAS G12C mutant solid tumors. ClinicalTrials.gov identifier: NCT05462717. Updated November 7, 2024. Accessed July 21, 2025. <a href=\\"https://clinicaltrials.gov/study/NCT05462717\\" target=\\"_blank\\">https://clinicaltrials.gov/study/NCT05462717</a>","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"Advanced solid tumors","descriptionTable":"RMC-6291-001 is a Phase 1/1b dose-escalation and dose-expansion study investigating the RAS(ON) inhibitor elironrasib (RMC-6291) in patients with advanced or metastatic solid tumors, including NSCLC, CRC, and PDAC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* KRAS G12C mutation\\r\\n* No primary central nervous system tumors or active brain metastasis\\r\\n* No major surgery within 28 days of first dose\\r\\n* No minor procedures within 7 days of treatment\\r\\n* Previously treated with standard of care (SOC) therapies for their respective tumor types, is intolerant to, or is considered ineligible for, SOC anticancer treatments\\r\\n* No previous treatment with a KRAS G12C(ON) inhibitor","statusTable":"active, not recruiting"},"NCT05379985":{"acronym":"RMC-6236-001","nctId":"NCT05379985","interventions":"Daraxonrasib (RMC-6236)","cardTitle":"Study of Daraxonrasib (RMC-6236) in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","overallStatus":"RECRUITING","status":"Active, RECRUITING","phaseNumber":1,"phase":"1/2 (open-label)","phase2":"","phaseFull":"Phase 1/Phase 2","conditionsForStudy":"* Non-small cell lung cancer (NSCLC)\\r\\n* Colorectal cancer (CRC)\\r\\n* Pancreatic ductal adenocarcinoma (PDAC)\\r\\n* Advanced solid tumors","conditions":"Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), advanced solid tumors","clinicalTrialPageDescription":"This study is designed to evaluate the safety and tolerability of daraxonrasib (RMC‑6236) in adults with specific RAS‑mutant advanced solid tumors.","clinicalTrialPageDescriptionMinimal":"Treatment na\xefve or previously treated advanced solid tumors haboring specific mutations in RAS","selectedEligibilityCriteria":"* Confirmed advanced disease\\r\\n* Histologically confirmed RAS and KRAS mutation status\\r\\n* Treatment na\xefve or received prior standard therapy\\r\\n* Adequate organ function\\r\\n* No active untreated brain metastases","eligibilityFootnote":"","startDate":"2022-05-31","completionDate":"2027-07-29","detailedDescription":"This is a **Phase 1/2**, multicenter open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of escalating doses of daraxonrasib in adult patients with advanced solid tumors harboring specific RAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended **Phase 2** dose (RP2D) within investigated patient population groups. Daraxonrasib is a potent, orally bioavailable RAS(ON) multi-selective inhibitor, selective for the active RAS(ON) form of both wild-type and mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS).","countries":"United States","allocation":"Not Applicable","primaryPurpose":"TREATMENT","enrollmentInfo":754,"interventionModel":"SINGLE GROUP\xa0ASSIGNMENT","leadSponsor":"Revolution Medicines, Inc.","studyType":"INTERVENTIONAL","masking":"NONE\xa0(open-label)","eligibilityCriteria":"**Inclusion Criteria:**\\r\\n\\r\\n* ≥18 years of age\\r\\n* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion)\\r\\n* Treatment na\xefve or received prior standard therapy appropriate for tumor type and stage\\r\\n* Eastern Cooperative Oncology Group Performance Status 0 or 1\\r\\n* Adequate organ function\\r\\n\\r\\n**Exclusion Criteria:**\\r\\n\\r\\n* Primary central nervous system (CNS) tumors\\r\\n* Active, untreated brain metastases\\r\\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication\\r\\n* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy","eligibilityCriteriaFootnote":"","primaryOutcomes":"Adverse events (AEs), dose-limiting toxicities (DLTs)","secondaryOutcomes":"Maximum observed blood concentration (C<sub>max</sub>), time to reach maximum blood concentration (T<sub>max</sub>), area under blood concentration time curve (AUC), accumulation ratio, elimination half-life (t1/2), overall response rate (ORR), duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS)","references":"Study of RMC-6236 in patients with advanced solid tumors harboring specific mutations in RAS. ClinicalTrials.gov identifier: NCT05379985. Updated November 12, 2025. Accessed November 26, 2025. <a href=\\"https://clinicaltrials.gov/study/NCT05379985\\" target=\\"_blank\\">https://clinicaltrials.gov/study/NCT05379985</a>","cancerTypeTable":"Advanced solid tumors, including PDAC, NSCLC, and colorectal cancer (CRC)","cancerTypeAbbr":"Advanced solid tumors","descriptionTable":"RMC-6236-001 a Phase 1/2 study that investigates the RAS(ON) inhibitor daraxonrasib (RMC‑6236) in adult patients with advanced solid tumors, including NSCLC, CRC, and PDAC","selectedEligibilityCriteriaTable":"* Male or female 18 years or older\\r\\n* KRAS G12 or RAS mutations\\r\\n* Treatment na\xefve or received prior standard therapy appropriate for tumor type and stage\\r\\n* No central nervous system tumors or active brain metastasis\\r\\n* No history of an unstable medical condition that could affect their ability to take part in the trial","statusTable":"actively recruiting"}}')},59434:(e,t,a)=>{a.d(t,{cn:()=>n});var i=a(52596),r=a(39688);function n(){for(var e=arguments.length,t=Array(e),a=0;a<e;a++)t[a]=arguments[a];return(0,r.QP)((0,i.$)(t))}},70248:(e,t,a)=>{a.d(t,{B:()=>p});var i=a(95155),r=a(59434),n=a(75196);let o={fadeIn:{hidden:{opacity:0},visible:{opacity:1,transition:{duration:1}}},slideUp:{hidden:{opacity:0,y:20},visible:{opacity:1,y:0,transition:{duration:1}}},staggerContainer:{hidden:{opacity:0},visible:{opacity:1,transition:{staggerChildren:.2,delayChildren:.1}}}},s={fadeIn:{variants:o.fadeIn,initial:"hidden",animate:"visible"},slideUp:{variants:o.slideUp,initial:"hidden",animate:"visible"},staggerContainer:{variants:o.staggerContainer,initial:"hidden",animate:"visible"},staggerItem:{variants:o.slideUp},default:{variants:{}}},l=e=>{switch(e){case"none":return"";case"top":return"rounded-t-full";case"bottom":return"rounded-b-full";case"all":return"rounded-full";case"top-left":return"rounded-tl-full";case"top-right":return"rounded-tr-full";case"bottom-left":return"rounded-bl-full";case"bottom-right":return"rounded-br-full"}},c=e=>{let{foregroundColor:t,backgroundColor:a,rounded:n="none",className:o}=e;return(0,i.jsxs)("div",{className:(0,r.cn)("relative isolate h-12 w-full",o),children:[(0,i.jsx)("div",{className:(0,r.cn)("absolute inset-0 -z-0",a)}),(0,i.jsx)("div",{className:(0,r.cn)("absolute inset-0 z-0",t,l(n))})]})},d=e=>{switch(e){case"full":return"col-span-full";case"two-thirds":return"col-span-full @4xl/grid-cols-24:col-span-16";case"half":return"col-span-full @2xl/grid-cols-24:col-span-12";case"third":return"col-span-full @2xl:@max-4xl/grid-cols-24:col-span-12 @4xl/grid-cols-24:col-span-8";case"quarter":return"col-span-full @2xl:@max-4xl/grid-cols-24:col-span-12 @4xl/grid-cols-24:col-span-6"}},u=e=>{switch(e){case"sm":return"pb-4";case"md":return"pb-8";case"lg":return"pb-28";case"none":return"pb-0"}},m=e=>{switch(e){case"sm":return"pt-4";case"md":return"pt-8";case"lg":return"pt-28";case"none":return"pt-0"}},p={Root:e=>{let{children:t,animation:a,motionProps:o,className:l}=e,c=a?s[a]:s.default;return(0,i.jsx)(n.P.div,{id:"stack-root",className:(0,r.cn)("stack-layout justify-center",l),...c,...o,children:t})},Item:{Root:e=>{let{children:t,bleed:a,background:o,animation:l,motionProps:d,className:u,id:m,topBump:p,bottomBump:h,after:y}=e,b=l?s[l]:s.default;return(0,i.jsxs)(n.P.div,{id:m,className:(0,r.cn)("relative col-span-full row-span-3 grid grid-cols-subgrid grid-rows-subgrid",u),...b,...d,children:[o&&(0,i.jsx)("div",{className:"stack-item-background -z-0 bg-cover bg-no-repeat!",children:o}),y&&(0,i.jsx)("div",{className:(0,r.cn)("absolute right-0 -bottom-12 left-0 h-12",y)}),p?(0,i.jsx)(c,{foregroundColor:p.foregroundColor,backgroundColor:p.backgroundColor,rounded:p.rounded,className:"stack-full-bleed bump-top"}):(0,i.jsx)("div",{className:"stack-full-bleed"}),(0,i.jsx)("div",{id:"stack-main-column",className:(0,r.cn)("relative grid max-w-full gap-24 sm:gap-40","full"===a?"stack-full-bleed":"half"===a?"stack-half-bleed":"stack-main"),children:(0,i.jsx)("div",{id:"grid-24-container",className:"@container/grid-cols-24 grid w-full grid-flow-dense grid-cols-24",children:t})}),h&&(0,i.jsx)(c,{foregroundColor:h.foregroundColor,backgroundColor:h.backgroundColor,rounded:h.rounded,className:"stack-full-bleed bump-botom"})]})},Subgrid:e=>{let{xGridSpan:t="full",pb:a="none",pt:o="none",children:l,animation:c,motionProps:p,animateOnView:h=!0,viewportOptions:y={once:!0,margin:"0px 0px -100px 0px"},className:b}=e,C={};if(c){let e=s[c];C=h?{variants:e.variants,initial:"hidden",whileInView:"visible",viewport:y}:e}return(0,i.jsx)(n.P.div,{id:"stack-subgrid-item",className:(0,r.cn)("@container isolate grid gap-2",d(t),u(a),m(o),b),...C,...p,children:l})}}}}}]);
